Alzheimer Disease Clinical Trial
— REMADOfficial title:
Study of Memory Problems Perceptions With the French Adaptation of the Illness Perception Questionnaire Memory, Among Patients Who Come for the First Time at a Memory Center Until Diagnosis Disclosure Post-visit
This study aims to prospectively examine the memory problem perceptions of patients with memory complaints [MCs] and their accompaniers during the diagnostic process.
Status | Recruiting |
Enrollment | 250 |
Est. completion date | November 2017 |
Est. primary completion date | November 2017 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: For patients with memory complaints: - Age over 18 years - Have a memory complaints with a QPC score greater than or equal to 3 - Be accompanied by a next of kin - Folstein MMSE greater than or equal to 15/30 - Have given their written consent after receiving clear and intelligible oral and written information - Social security coverage For Accompaniers : - Age over 18 years - Consent to participate at the study with the patient - Have given their written consent after receiving clear and intelligible oral and written information - Social security coverage - Be in contact with the patient at least 8 hours per week. It could be physical contact or telephone contact. Exclusion Criteria: For patients with memory complaints: - Sensory deficit interfering with the completion of the questionnaires - Level of French insufficient to complete the questionnaires - Legally protected person - Diagnosis of neurocognitive disorders already established - Treatment for Alzheimer Disease - Refusal or inability to obtain written informed consent form from the patient - Included in another experimental study at inclusion visit For Accompaniers: - Sensory deficit interfering with the completion of the questionnaires - Level of French insufficient to complete the questionnaires - Refusal or inability to obtain written informed consent form from the accompanier |
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
France | University Hospital of Nancy ,CHU Brabois, France | Vandoeuvre les Nancy |
Lead Sponsor | Collaborator |
---|---|
Central Hospital, Nancy, France | Laboratoire APEMAC :Maladies chroniques, santé perçue, processus d adaptation, France, Union des associations France Alzheimer et maladies apparentées, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Memory problems perceptions of patients and next of kin during diagnosis process | How patients and accompaniers perceive memory problems at the first visit in a Memory Center to 6 months after the diagnosis disclosure, with the Illness Perception Questionnaire Memory | Baseline and 6 months after diagnosis disclosure | No |
Secondary | Psychometric properties of the french adaptation of the Ilness Perceptions Questionnaire - Memory (IPQ-M, Hurt et al. 2010) | Psychometric properties of IPQ-M by a traditional approach and by comparison to another french memory complaint questionnaire | Baseline, 1 month later and 6 months after diagnosis disclosure | No |
Secondary | Impact of the memory problems perceptions on mood and well-being | Correlation between memory problems perceptions at the IPQ-M, levels of anxiety (STAI-Y), depression (MADRS), quality of life (WHOQOL-BREF) and coping strategies. | Baseline and 6 months after diagnosis disclosure | No |
Secondary | Differences of memory problems perceptions and coping according to level of cognitive disorder at the Mini-Mental State Examination (MMSE) | Baseline and 6 months after diagnosis disclosure | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |